Trial · NCT07905274
Sarcopenia Risk in Obese T2DM Patients
NCT07905274, Not yet recruiting, Bandırma Onyedi Eylül University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sarcopenia Risk in Obese T2DM Patients. Trials, record NCT07905274. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905274
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sarcopenia Risk in Obese T2DM Patients
- NCT number
- NCT07905274
- Status
- Not yet recruiting
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Bandırma Onyedi Eylül University
- Conditions
- Sarcopenia, Obesity Type 2 Diabetes Mellitus
- Interventions
- physical examination, physical examination, physical examination, physical examination
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | risk of sarcopenia | through study completion, an average of 1 year | SARC-F survey. Scale Title: Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls (SARC-F) Questionnaire. Score Range: 0-10 points. Interpretation: Higher scores indicate a higher risk of sarcopenia and greater severity of sarcopenia-related symptoms and functional limitations. A total score of 4 or higher indicates a positive screening result for sarcopenia risk. |
| Secondary | muscle strength | through study completion, an average of 1 year | Hand grip strength Hand grip strength will be assessed using a hand dynamometer. Grip strength will be measured in kilograms (kg). Higher values indicate greater muscle strength, whereas lower values indicate reduced muscle strength and may be associated with an increased risk of sarcopenia. |
| Secondary | lower-extremity strength, functional capacity, and fall risk | through study completion, an average of 1 year | Five-times sit-to-stand test Description: The Five-Times Sit-to-Stand Test (5xSTS) will be used to assess lower extremity muscle strength and functional performance. Participants will be instructed to stand up from a seated position and sit down five consecutive times as quickly as possible, with their arms crossed over their chest, without using their arms for support. The time required to complete all five repetitions will be recorded in seconds. Interpretation: Shorter completion times indicate better lower extremity muscle strength and functional performance, whereas longer completion times indicate poorer functional performance and may be associated with an increased risk of sarcopenia. |
| Secondary | general health status, physical condition | through study completion, an average of 1 year | The 4-meter walk test Description: The 4-Meter Walk Test (4MWT) will be used to assess usual gait speed as an indicator of physical performance. Participants will be instructed to walk a 4-meter distance at their usual comfortable walking speed. The time required to complete the distance will be recorded in seconds, and gait speed will be calculated in meters per second (m/s) by dividing the distance walked by the completion time. Interpretation: Higher gait speed values indicate better physical performance, whereas lower gait speed values indicate poorer physical performance and may be associated with an increased risk of sarcopenia. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905274
GET https://conductscience.org/api/trials/v1/NCT07905274/registered